The Efficacy of Red Grape Seed Extract on Lipid Profile and Oxidized Low-Density Lipoprotein (OX-LDL) (GSE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Antioxidants are potent scavengers of free radicals and serve as inhibitors of neoplastic processes. A large number of synthetic and natural antioxidants are known to induce beneficial effects on human health and disease prevention. Cardioprotective ability of grape seed extract polyphenols (GSEP) was studied in animals and humans. It has been suggested that grape seed proanthocyanidins have cardioprotective effects against reperfusion-induced injury of free radicals after ischemia. In another study, it is suggested that proanthocyanidins, the major polyphenols in red wine, might trap reactive oxygen species in aqueous series such as plasma and interstitial fluid of the arterial wall; thereby inhibiting oxidation of low-density lipoprotein (LDL) and showing an antiatherosclerotic activity. The only human model study designed to evaluate the effect of a standardized formulation of a GSEP (leucoselect-phytosome [LP]) on the susceptibility of LDL to oxidation in a group of heavy smokers, revealed that the antioxidant potential of GSEP may be effective in oxidative stress (smoking); however more investigational data are needed before wider use in clinical settings. Based on these observations, the investigators decided to evaluate the effect of GSEP in reducing OX-LDL in patients diagnosed with mild hyperlipidemia.
| Condition | Intervention | Phase |
|---|---|---|
|
Hyperlipidemia |
Drug: Grape Seed Extract (Vitagrape) Drug: Placebo of Grape Seed Extract |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Randomized, Cross-Over, Double Blind, Placebo-Controlled Study of Grape Seed Extract in Treating Patients With Mild Hyperlipidemia |
- OX-LDL [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- LDL [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- HDL [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- Blood Pressure [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- Triglyceride [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- Total Cholesterol [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- Body Mass Index [ Time Frame: 8 weeks -{45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
- LDL/HDL [ Time Frame: 8 weeks- {45 days wash out, crossed }- 8 weeks after crossed ] [ Designated as safety issue: No ]
| Enrollment: | 55 |
| Study Start Date: | July 2008 |
| Study Completion Date: | February 2009 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Grape Seed Extract
Enrolled patients who are randomly assigned to receive Grape Seed Extract capsules
|
Drug: Grape Seed Extract (Vitagrape)
Drug {Each Containing: Grape Seed Extract100 mg +...} 1 capsule twice daily for 2 months Other Names:
|
|
Placebo Comparator: Placebo
Placebo enrolled patients who are randomly assigned to receive placebo of Grape Seed Extract
|
Drug: Placebo of Grape Seed Extract
Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg} 1 capsule twice daily for 2 months |
Eligibility| Ages Eligible for Study: | 21 Years to 64 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Triglyceride > 150 mg/dl
- Total Cholesterol > 200 mg/dl
Exclusion Criteria:
- Severe hyperlipidemia (Triglyceride > 300 mg/dl,Total Cholesterol > 250 mg/dl)
- Usage of antilipid drugs
- Herbivore Diet
- Alcoholism
- Heart failure
- Known cases of any malignancy
- BMI > 30 kg/M2
- Chronic Hepatic Diseases
- Smoking
- Chronic Renal Failure
Contacts and Locations| Iran, Islamic Republic of | |
| Ghorbanihaghjo | |
| Tabriz, East Azarbayejan, Iran, Islamic Republic of, ------ | |
| Maryam | |
| Tehran, Iran, Islamic Republic of, 19814 | |
| Study Director: | Maryam Keshtkar-Jahromi, MD, | Shahid Beheshti University (MC) |
| Study Chair: | Hassan Argani, MD | Shahid Beheshti University (MC) |
| Principal Investigator: | Abbas Delazar, PhD | Tabriz University |
| Principal Investigator: | Ali Eskandari, MD | Shahid Beheshti University (MC) |
| Principal Investigator: | Sharareh Gholamin, MD | Shahid Beheshti University (MC) |
| Principal Investigator: | Seyed Mostafa Razavi, MD | Shahid Beheshti University (MC) |
More Information
Publications:
| Responsible Party: | Maryam Keshtkar Jahromi, Shahid Beheshti University (MC) |
| ClinicalTrials.gov Identifier: | NCT00713167 History of Changes |
| Other Study ID Numbers: | SBMU 87-01-106-5694 |
| Study First Received: | July 8, 2008 |
| Last Updated: | May 20, 2009 |
| Health Authority: | Iran: Ministry of Health |
Keywords provided by Shaheed Beheshti Medical University:
|
Grape Seed Extract Hyperlipidemia |
Additional relevant MeSH terms:
|
Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Grape Seed Extract Antineoplastic Agents, Phytogenic Antineoplastic Agents |
Therapeutic Uses Pharmacologic Actions Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 23, 2013